Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Forsta AP Fonden

Forsta AP Fonden grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 94,070 shares of the medical research company's stock after buying an additional 8,500 shares during the period. Forsta AP Fonden's holdings in Thermo Fisher Scientific were worth $58,189,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Signature Resources Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock valued at $25,000 after buying an additional 35 shares during the period. New Millennium Group LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth $29,000. Stephens Consulting LLC boosted its position in Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock worth $30,000 after purchasing an additional 29 shares during the period. Headlands Technologies LLC purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth $32,000. Finally, Bank & Trust Co purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth $33,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Marc N. Casper sold 6,300 shares of the stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $602.09, for a total value of $3,793,167.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,548,375.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company's stock, valued at $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Sanford C. Bernstein decreased their price target on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating for the company in a research report on Thursday. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a report on Thursday. Bank of America boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Bernstein Bank boosted their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a report on Tuesday. Finally, Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an "outperform" rating in a report on Thursday, July 25th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $649.33.

Thermo Fisher Scientific Stock Performance

TMO traded down $3.00 on Friday, hitting $554.38. 1,090,373 shares of the company's stock were exchanged, compared to its average volume of 1,467,407. Thermo Fisher Scientific Inc. has a twelve month low of $420.21 and a twelve month high of $627.88. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The firm has a market cap of $211.77 billion, a PE ratio of 34.39, a P/E/G ratio of 3.75 and a beta of 0.77. The stock has a fifty day moving average of $605.12 and a two-hundred day moving average of $584.04.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. During the same quarter in the prior year, the firm earned $5.69 EPS. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.